AR015176A1 - Derivados pirazol y derivados de pirazol condensados que incluyen indazoles, su procedimiento de preparacion, preparado farmaceutico y su utilizacionpara la preparacion de medicamentos. - Google Patents
Derivados pirazol y derivados de pirazol condensados que incluyen indazoles, su procedimiento de preparacion, preparado farmaceutico y su utilizacionpara la preparacion de medicamentos.Info
- Publication number
- AR015176A1 AR015176A1 ARP980104944A ARP980104944A AR015176A1 AR 015176 A1 AR015176 A1 AR 015176A1 AR P980104944 A ARP980104944 A AR P980104944A AR P980104944 A ARP980104944 A AR P980104944A AR 015176 A1 AR015176 A1 AR 015176A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- radicals
- cycloalkyl
- het
- aryl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Vascular Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Derivados pirazoles y de pirazoles condensados que incluyen indazoles, caracterizados porque comprenden compuestos de la formula (I), en la que: Xrepresenta O, S, NH o N(CH3); R1 y R1a, independientemente uno de otro, representan hidrogeno, halogeno,OR6, NR7R8, CO-OR9, CO-R10, CO-NR11R12, CO-NR12-OR11,S(O)m-R13, S(O)2-NR14R15, CN, NO2, alquilo C1-10, arilo C6-14, aril C6-14-alquilo C1-4, cicloalquilo C3-7, cicloalquil C3-7-alquilo C1-4, el radical Heto el radical Het-alquilo C1-4, pudiendo losradicales alquilo, radicales arilo, radicales arialquilo, radicales cicloalquilo, radicales cicloalquil-alquilo,así como los radicales Het y Het-alquilo, que se presentan por R1 y R1a, estar en cada caso sin sustituir o sustituidos con uno o varios sustituyentes R5, ypudiendo R1 representar NO2 solo cuando simultáneamente R1a representa hidrogeno, los radicales R2 y R3, en comun con los átomos de carbono que los llevan,forman un anillo de benceno sin sustituir o un anillo de benceno sustituido con uno o varios sustituyentes R5, n representa 0 y el resto -(CH2)-R4 tieneun significado distinto del de fenilo sin sustituir; R2 y R3, independientemente uno de otro, representan hidrogeno, alquilo halogeno, alquilo C1-10, ariloC6-14, aril C6-14-alquilo C1-4, cicloalquilo C3-7, cicloalquil C3-7-alquilo C1-4, el radical Het o el radical Het-alquilo C1-4, pudiendo los radicalesalquilo, radicales arilo, radicales arialquilo, radicales cicloalquilo, radicales cicloalquil-alquilo, así como los radicales Het y Het-alquilo, que sepresentan por R2 y R3, estar en cada caso sin sustituir o sustituidos con uno o varios sustituyentes R5, o R2 y R3, en comun con los átomos de carbonoque los llevan, forman un anillo carbocíclico de 5 hasta 7 miembros,que puede contener uno o varios dobles enlaces y que puede estar sin sustituir osustituido con uno o varios sustituyentes R5; R4 representa hidrogeno, alquilo C1-10, arilo C6-14, aril C6-14-alquilo C1-4, cicloalquilo C3-7, cicloalquilC3-7-alquilo C1-4, el radical Het o el radical Het-alquilo C1-4, pudiendo los radicales alquilo, radicales arilo, radicales arialquilo, radicales
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19744026A DE19744026A1 (de) | 1997-10-06 | 1997-10-06 | Pyrazol-Derivate, ihre Herstellung und ihre Verwendung in Arzneimitteln |
Publications (1)
Publication Number | Publication Date |
---|---|
AR015176A1 true AR015176A1 (es) | 2001-04-18 |
Family
ID=7844687
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP980104944A AR015176A1 (es) | 1997-10-06 | 1998-10-02 | Derivados pirazol y derivados de pirazol condensados que incluyen indazoles, su procedimiento de preparacion, preparado farmaceutico y su utilizacionpara la preparacion de medicamentos. |
Country Status (19)
Country | Link |
---|---|
US (3) | US6162819A (es) |
EP (2) | EP1418176B1 (es) |
JP (1) | JP4426660B2 (es) |
KR (1) | KR19990036814A (es) |
CN (1) | CN1214339A (es) |
AR (1) | AR015176A1 (es) |
AT (2) | ATE256680T1 (es) |
AU (1) | AU749595B2 (es) |
BR (1) | BR9803880A (es) |
CA (1) | CA2249542C (es) |
CZ (1) | CZ320598A3 (es) |
DE (3) | DE19744026A1 (es) |
DK (2) | DK0908456T3 (es) |
ES (2) | ES2345249T3 (es) |
HU (1) | HUP9802224A1 (es) |
ID (1) | ID21019A (es) |
PL (1) | PL329042A1 (es) |
PT (2) | PT1418176E (es) |
TR (1) | TR199801996A2 (es) |
Families Citing this family (103)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU751139B2 (en) | 1997-10-13 | 2002-08-08 | Astellas Pharma Inc. | Amide derivative |
KR19990080440A (ko) * | 1998-04-17 | 1999-11-05 | 성재갑 | 신규한 피라졸 유도체 |
KR19990085450A (ko) * | 1998-05-18 | 1999-12-06 | 성재갑 | 피라졸 구조를 갖는 새로운 mek 단백질 저해제 |
HU228111B1 (en) | 1998-07-08 | 2012-11-28 | Sanofi Aventis Deutschland | Sulfur substituted sulfonylaminocarboxylic acid n-arylamides, their preparation, their use and pharmaceutical preparations comprising them |
DE19836697A1 (de) * | 1998-08-13 | 2000-02-17 | Hoechst Marion Roussel De Gmbh | Substituierte 4-Amino-2-aryl-pyrimidine, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate |
DE19944226A1 (de) * | 1999-09-15 | 2001-03-29 | Aventis Pharma Gmbh | Verfahren zum Nachweis von oxidierten Formen der löslichen Guanylatzyklase und Verfahren zum Screening nach Aktivatoren der löslichen Guanylatzyklase mit oxidiertem Hämeisen |
JP2003513064A (ja) * | 1999-11-05 | 2003-04-08 | ユニバーシティ カレッジ ロンドン | 可溶性グアニル酸シクラーゼのアクチベーター |
US6362213B1 (en) | 1999-12-23 | 2002-03-26 | Icos Corporation | Cyclic AMP-specific phosphodiesterase inhibitors |
YU54202A (sh) * | 2000-01-18 | 2006-01-16 | Agouron Pharmaceuticals Inc. | Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije |
GB0003154D0 (en) * | 2000-02-12 | 2000-04-05 | Astrazeneca Uk Ltd | Novel compounds |
US6387942B2 (en) | 2000-06-19 | 2002-05-14 | Yung Shin Pharmaceutical Ind. Co. Ltd | Method of treating disorders related to protease-activated receptors-induced cell activation |
KR20050117594A (ko) * | 2000-06-23 | 2005-12-15 | 주식회사 하이닉스반도체 | 반도체 소자의 제조 방법 |
US6610726B2 (en) * | 2001-06-29 | 2003-08-26 | North Shore-Long Island Jewish Research Institute | Compositions and agents for modulating cellular proliferation and angiogenesis |
US6589997B2 (en) * | 2001-06-29 | 2003-07-08 | North Shore-Long Island Jewish Health System | Small-molecule modulators of hepatocyte growth factor/scatter factor activities |
SE0102617D0 (sv) | 2001-07-25 | 2001-07-25 | Astrazeneca Ab | Novel compounds |
SE0102616D0 (sv) | 2001-07-25 | 2001-07-25 | Astrazeneca Ab | Novel compounds |
US7049334B2 (en) * | 2001-09-14 | 2006-05-23 | Carlsbad Technology, Inc. | Enhancement of learning and memory and treatment of amnesia |
US20040077702A1 (en) * | 2001-09-14 | 2004-04-22 | Wen-Mei Fu | Treatment of nuerodegenerative diseases |
US7345079B2 (en) | 2001-12-26 | 2008-03-18 | Yung Shin Pharmaceuticals Industrial Co., Ltd | Treatment of disorder related to low cyclic GMP levels |
TWI264304B (en) * | 2002-01-25 | 2006-10-21 | Yung Shin Pharm Ind Co Ltd | Methods of treating sepsis |
US20050209252A1 (en) * | 2002-03-29 | 2005-09-22 | Che-Ming Teng | Cancer treatment |
US7166293B2 (en) * | 2002-03-29 | 2007-01-23 | Carlsbad Technology, Inc. | Angiogenesis inhibitors |
US20050119278A1 (en) * | 2002-05-16 | 2005-06-02 | Che-Ming Teng | Anti-angiogenesis methods |
SE0300091D0 (sv) | 2003-01-15 | 2003-01-15 | Astrazeneca Ab | Novel compounds |
SE0300092D0 (sv) | 2003-01-15 | 2003-01-15 | Astrazeneca Ab | Novel compounds |
GB0302094D0 (en) | 2003-01-29 | 2003-02-26 | Pharmagene Lab Ltd | EP4 receptor antagonists |
US20050096370A1 (en) * | 2003-04-07 | 2005-05-05 | Bizbiotech Co., Ltd. | Method for inhibiting tumor angiogenesis and tumor growth |
WO2005030121A2 (en) * | 2003-06-30 | 2005-04-07 | Hif Bio, Inc. | Compounds, compositions and methods |
JP2005089457A (ja) * | 2003-09-03 | 2005-04-07 | Yung Shin Pharmaceutical Industry Co Ltd | 骨成長を促進するまたは骨吸収を阻害するための薬剤組成物 |
GB0324269D0 (en) * | 2003-10-16 | 2003-11-19 | Pharmagene Lab Ltd | EP4 receptor antagonists |
EP1576954A1 (en) * | 2004-03-15 | 2005-09-21 | Yung Shin Pharm. Ind. Co. Ltd. | Preferential inhibition of release of pro-inflammatory cytokines |
US7378532B2 (en) * | 2004-03-26 | 2008-05-27 | Yung Shin Pharmaceutical Ind. Co., Ltd. | Fused pyrazolyl compound |
AR050279A1 (es) * | 2004-08-03 | 2006-10-11 | Wyeth Corp | Indazoles como moduladores de lxr utiles en la preparacion de medicamentos pata el tratamiento de enfermedades cardiovasculares y mediadas por th1 y composiciones farmaceuticas que los contienen como principio activo. |
DE102004051277A1 (de) * | 2004-10-21 | 2006-04-27 | Merck Patent Gmbh | Heterocyclische Carbonylverbindungen |
CA2637335A1 (en) | 2006-01-23 | 2007-08-02 | Vertex Pharmaceuticals Incorporated | Thiophene-carboxamides useful as inhibitors of protein kinases |
ES2462240T3 (es) * | 2006-02-28 | 2014-05-22 | Dart Neuroscience (Cayman) Ltd | Piperazinas terapéuticas como inhibidores de PDE4 |
NZ595571A (en) * | 2006-02-28 | 2013-04-26 | Helicon Therapeutics Inc | Pyrazole compounds and uses thereof |
JP2009533452A (ja) * | 2006-04-13 | 2009-09-17 | バーテックス ファーマシューティカルズ インコーポレイテッド | タンパク質キナーゼの阻害剤として有用なチオフェン−カルボキサミド |
US8853244B2 (en) * | 2006-05-23 | 2014-10-07 | Vertex Pharmaceuticals Incorporated | Thiophene-carboxamides useful as inhibitors of protein kinases |
CN101495474A (zh) | 2006-05-23 | 2009-07-29 | 沃泰克斯药物股份有限公司 | 可用作蛋白激酶抑制剂的噻吩-甲酰胺类 |
UY30892A1 (es) | 2007-02-07 | 2008-09-02 | Smithkline Beckman Corp | Inhibidores de la actividad akt |
US20080252028A1 (en) * | 2007-04-16 | 2008-10-16 | Ming-Tai Huang | Shock absorbing device for toy stroller |
BRPI0812361A2 (pt) * | 2007-05-18 | 2015-02-03 | Bayer Schering Pharma Ag | Derivados de pirazol heteroaril-substituídos úteis parao tratamento de distúrbios e doenças hiperproliferativos associados à angiogênese |
MX2010002258A (es) | 2007-08-27 | 2010-04-22 | Helicon Therapeutics Inc | Compuestos terapeuticos de isoxazol. |
BRPI0816382A2 (pt) | 2007-09-06 | 2015-02-24 | Merck Sharp & Dohme | Composto, composição, e, métodos para ativar a guanilato ciclase solúvel e para tratar ou previnir doenças |
CA2720343A1 (en) | 2008-04-04 | 2009-10-08 | Takeda Pharmaceutical Company Limited | Heterocyclic derivative and use thereof |
DE102008057364A1 (de) | 2008-11-14 | 2010-05-20 | Bayer Schering Pharma Aktiengesellschaft | Substituierte Aryl-Verbindungen und ihre Verwendung |
DE102009041242A1 (de) | 2009-09-11 | 2011-12-15 | Bayer Schering Pharma Aktiengesellschaft | Heterocyclisch substituierte Aryl-Verbindungen und ihre Verwendung |
DE102008057344A1 (de) | 2008-11-14 | 2010-05-20 | Bayer Schering Pharma Aktiengesellschaft | Aminoalkyl-substituierte Aryl-Verbindungen und ihre Verwendung |
DE102009041241A1 (de) | 2009-09-11 | 2011-08-04 | Bayer Schering Pharma Aktiengesellschaft, 13353 | Substituierte Aryl-Verbindungen und ihre Verwendung |
DE102008057343A1 (de) | 2008-11-14 | 2010-05-20 | Bayer Schering Pharma Aktiengesellschaft | Heterocyclisch substituierte Aryl-Verbindungen und ihre Verwendung |
AU2009322836B2 (en) | 2008-11-25 | 2013-04-04 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
DE102009004245A1 (de) * | 2009-01-09 | 2010-07-15 | Bayer Schering Pharma Aktiengesellschaft | Neue anellierte, Heteroatom-verbrückte Pyrazol- und Imidazol-Derivate und ihre Verwendung |
PE20120003A1 (es) | 2009-01-30 | 2012-02-12 | Glaxosmithkline Llc | Hidrocloruro de n-{(1s)-2-amino-1-[(3-fluorofenil)metil)etil}-5-cloro-4-(4-cloro-1-metil-1h-pirazol-5-il)-2-tiofenocarboxamida cristalino |
AU2010218224B2 (en) | 2009-02-26 | 2013-06-27 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
GB0917238D0 (en) * | 2009-10-01 | 2009-11-18 | Univ London | Blockade of voltage dependent sodium channels |
WO2011115804A1 (en) | 2010-03-17 | 2011-09-22 | Ironwood Pharmaceuticals, Inc. | Sgc stimulators |
WO2011119518A1 (en) | 2010-03-25 | 2011-09-29 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
EP2575473B1 (en) | 2010-05-27 | 2016-01-20 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
DK2588465T3 (en) | 2010-06-30 | 2017-05-01 | Ironwood Pharmaceuticals Inc | SGC stimulators |
WO2012058132A1 (en) | 2010-10-28 | 2012-05-03 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
US9061030B2 (en) * | 2010-11-09 | 2015-06-23 | Ironwood Pharmaceuticals, Inc. | sGC stimulators |
KR20120098489A (ko) * | 2011-02-28 | 2012-09-05 | 이화여자대학교 산학협력단 | 피라졸 유도체를 포함하는 심혈관 질환 예방 및 치료용 조성물 |
EP3112363A1 (en) | 2011-12-27 | 2017-01-04 | Ironwood Pharmaceuticals, Inc. | 2-[1-[(2-fluorophenyl)methyl]-5-(3-isoxazolyl)-1h-pyrazol-3-yl]-pyrimidine derivatives and related compounds as soluble guanylate cyclase (sgc) stimulators for the treatment of pulmonary hypertension |
JO3215B1 (ar) | 2012-08-09 | 2018-03-08 | Phenex Pharmaceuticals Ag | حلقات غير متجانسة بها 5 ذرات تحتوي على النيتروجين بها استبدال بكربوكساميد أو سلفوناميد كمعدلات لمستقبل نووي غير محمي RORy |
US9309235B2 (en) * | 2012-09-18 | 2016-04-12 | Ironwood Pharmaceuticals, Inc. | SGC stimulators |
US9487508B2 (en) | 2012-09-19 | 2016-11-08 | Ironwood Pharmaceuticals, Inc. | SGC stimulators |
MX361208B (es) | 2013-03-15 | 2018-11-30 | Ironwood Pharmaceuticals Inc | Estimuladores de guanilato ciclasa soluble (sgc). |
EP3079701B1 (en) | 2013-12-11 | 2021-08-11 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
US9783552B2 (en) | 2013-12-11 | 2017-10-10 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
EA032028B1 (ru) | 2013-12-11 | 2019-03-29 | Айронвуд Фармасьютикалз, Инк. | СТИМУЛЯТОРЫ рГЦ |
WO2015106268A1 (en) | 2014-01-13 | 2015-07-16 | Ironwood Pharmaceuticals, Inc. | USE OF sGC STIMULATORS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS |
CA2961489A1 (en) | 2014-09-17 | 2016-03-24 | Glen Robert RENNIE | Sgc stimulators |
CA2959757A1 (en) | 2014-09-17 | 2016-03-24 | Ironwood Pharmaceuticals, Inc. | Pyrazole derivatives as sgc stimulators |
WO2016044445A2 (en) | 2014-09-17 | 2016-03-24 | Ironwood Pharmaceuticals, Inc. | sGC STIMULATORS |
TW201625635A (zh) | 2014-11-21 | 2016-07-16 | 默沙東藥廠 | 作為可溶性鳥苷酸環化酶活化劑之三唑并吡基衍生物 |
WO2016191334A1 (en) | 2015-05-27 | 2016-12-01 | Merck Sharp & Dohme Corp. | Imidazo-pyrazinyl derivatives useful as soluble guanylate cyclase activators |
US10213429B2 (en) | 2015-05-28 | 2019-02-26 | Merck Sharp & Dohme Corp. | Imidazo-pyrazinyl derivatives useful as soluble guanylate cyclase activators |
EA201891416A1 (ru) | 2015-12-14 | 2018-12-28 | Айронвуд Фармасьютикалз, Инк. | ПРИМЕНЕНИЕ СТИМУЛЯТОРОВ sGC ДЛЯ ЛЕЧЕНИЯ ДИСФУНКЦИИ ЖЕЛУДОЧНО-КИШЕЧНОГО СФИНКТЕРА |
WO2017107052A1 (en) | 2015-12-22 | 2017-06-29 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase stimulators |
WO2017197555A1 (en) | 2016-05-16 | 2017-11-23 | Merck Sharp & Dohme Corp. | Fused pyrazine derivatives useful as soluble guanylate cyclase stimulators |
WO2017200857A1 (en) | 2016-05-18 | 2017-11-23 | Merck Sharp & Dohme Corp. | Methods for using triazolo-pyrazinyl soluble guanylate cyclase activators in fibrotic disorders |
EP3481837B1 (en) | 2016-07-07 | 2023-12-06 | Cyclerion Therapeutics, Inc. | Phosphorus prodrugs of sgc stimulators |
MA45588A (fr) | 2016-07-07 | 2019-05-15 | Ironwood Pharmaceuticals Inc | Formes solides d'un stimulateur de la gcs |
CR20220309A (es) | 2016-09-02 | 2022-09-16 | Cyclerion Therapeutics Inc | Estimuladores de sgc |
SG10202104865UA (en) | 2016-11-08 | 2021-06-29 | Cyclerion Therapeutics Inc | Treatment of cns diseases with sgc stimulators |
MA46755A (fr) | 2016-11-08 | 2021-06-02 | Cyclerion Therapeutics Inc | Stimulateurs de sgc |
US20190381039A1 (en) | 2016-12-13 | 2019-12-19 | Cyclerion Therapeutics, Inc. | USE OF sGC STIMULATORS FOR THE TREATMENT OF ESOPHAGEAL MOTILITY DISORDERS |
AU2018252099B2 (en) | 2017-04-11 | 2021-08-12 | Sunshine Lake Pharma Co., Ltd. | Fluorine-substituted indazole compounds and uses thereof |
CN108948002A (zh) * | 2017-05-19 | 2018-12-07 | 厦门大学 | 五元并六元氮杂芳环类化合物、其制备方法、药用组合物及其应用 |
JP7337067B2 (ja) | 2017-12-19 | 2023-09-01 | サイクレリオン・セラピューティクス,インコーポレーテッド | sGC刺激薬 |
PE20210124A1 (es) | 2018-03-07 | 2021-01-19 | Cyclerion Therapeutics Inc | FORMAS CRISTALINAS DE UN ESTIMULANTE DE LA GUANILIL CICLASA SOLUBLE (sGC) |
US20210177846A1 (en) | 2018-07-11 | 2021-06-17 | Cyclerion Therapeutics, Inc. | USE OF sGC STIMULATORS FOR THE TREATMENT OF MITOCHONDRIAL DISORDERS |
KR102212344B1 (ko) * | 2019-04-26 | 2021-02-05 | 영남대학교 산학협력단 | 피라졸 골격을 가진 퓨란 고리 화합물, 이의 유도체 및 이의 합성방법 |
US20230130739A1 (en) | 2020-03-26 | 2023-04-27 | Cyclerion Therapeutics, Inc. | DEUTERATED sGC STIMULATORS |
US20230128032A1 (en) | 2020-03-31 | 2023-04-27 | Curtails Llc | Early Drug Interventions to Reduce COVID-19 Related Respiratory Distress, Need for Respirator Assist and Death |
BR112023021851A2 (pt) | 2021-04-20 | 2024-02-06 | Tisento Therapeutics Inc | Estimulantes de sgc |
EP4326268A1 (en) | 2021-04-20 | 2024-02-28 | Tisento Therapeutics Inc. | Treatment of cns diseases with sgc stimulators |
CN113274391B (zh) * | 2021-06-01 | 2022-07-05 | 苏州大学 | 吡唑衍生物在制备p2y6r相关治疗动脉粥样硬化及抗炎药物中的应用 |
WO2022265984A1 (en) | 2021-06-14 | 2022-12-22 | Curtails Llc | Use of nep inhibitors for the treatment of gastrointestinal sphincter disorders |
WO2023018795A1 (en) | 2021-08-11 | 2023-02-16 | Curtails Llc | Nep inhibitors for the treatment of laminitis |
WO2024086179A1 (en) | 2022-10-18 | 2024-04-25 | Tisento Therapeutics, Inc. | Pyrimidine sgc stimulators |
WO2024086182A1 (en) | 2022-10-18 | 2024-04-25 | Tisento Therapeutics Inc. | Treatment of mitochondrial diseases with sgc stimulators |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4146721A (en) * | 1969-09-12 | 1979-03-27 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Pyrazol-4-acetic acid compounds |
DE2141124A1 (en) * | 1969-09-12 | 1972-02-24 | Byk-Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz | Heterocyclic substituted pyrazole-4-acetic acids |
CH518155A (de) * | 1970-08-18 | 1972-01-31 | Schaerer Willy | Verfahren zur Erleichterung des Schleifens schraubenlinienförmiger Nuten, bei einer Serie von unter sich gleichen Werkstücken mit je mindestens einer schraubenlinienförmig eingefrästen Nut und Simuliergerät zur Durchführung des Verfahrens |
FR2104932A1 (en) * | 1970-09-08 | 1972-04-28 | Ferlux | O-hydroxyphenyl pyrazoles - hypocholesterolemics anti inflammatories analgesics etc |
JPS50121271A (es) * | 1974-03-12 | 1975-09-23 | ||
NZ178996A (en) * | 1974-11-15 | 1978-06-02 | Kornis G | Pyrfazole amides and thioamides;herbicidal compositions |
US5434178A (en) * | 1993-11-30 | 1995-07-18 | G.D. Searle & Co. | 1,3,5 trisubstituted pyrazole compounds for treatment of inflammation |
JP2928079B2 (ja) * | 1994-02-14 | 1999-07-28 | 永信薬品工業股▲ふん▼有限公司 | 1−(置換ベンジル)−3−(置換アリール)縮合ピラゾール類、その製造法及びその用途 |
JP3964478B2 (ja) * | 1995-06-30 | 2007-08-22 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | ヘテロ環含有カルボン酸誘導体及びそれを含有する医薬 |
DE19642255A1 (de) * | 1996-10-14 | 1998-04-16 | Bayer Ag | Verwendung von 1-Benzyl-3-(substituierten-hetaryl) -kondensierten Pyrazol-Derivaten |
PL332871A1 (en) * | 1996-10-14 | 1999-10-25 | Bayer Ag | Novel heterocyclylmethyl-substituted derivative of pyrazole |
DE19649460A1 (de) * | 1996-11-26 | 1998-05-28 | Bayer Ag | Neue substituierte Pyrazolderivate |
US6451805B1 (en) * | 1997-11-14 | 2002-09-17 | Bayer Aktiengesellschaft | Substituted pyrazole derivatives for the treatment of cardiocirculatory diseases |
-
1997
- 1997-10-06 DE DE19744026A patent/DE19744026A1/de not_active Withdrawn
-
1998
- 1998-09-30 EP EP03028260A patent/EP1418176B1/de not_active Expired - Lifetime
- 1998-09-30 DK DK98118494T patent/DK0908456T3/da active
- 1998-09-30 ES ES03028260T patent/ES2345249T3/es not_active Expired - Lifetime
- 1998-09-30 ES ES98118494T patent/ES2212192T3/es not_active Expired - Lifetime
- 1998-09-30 DE DE59814449T patent/DE59814449D1/de not_active Expired - Lifetime
- 1998-09-30 PT PT03028260T patent/PT1418176E/pt unknown
- 1998-09-30 EP EP98118494A patent/EP0908456B1/de not_active Expired - Lifetime
- 1998-09-30 AT AT98118494T patent/ATE256680T1/de active
- 1998-09-30 DK DK03028260.2T patent/DK1418176T3/da active
- 1998-09-30 DE DE59810448T patent/DE59810448D1/de not_active Expired - Lifetime
- 1998-09-30 AT AT03028260T patent/ATE466011T1/de active
- 1998-09-30 PT PT98118494T patent/PT908456E/pt unknown
- 1998-10-02 ID IDP981320A patent/ID21019A/id unknown
- 1998-10-02 KR KR1019980041567A patent/KR19990036814A/ko not_active Application Discontinuation
- 1998-10-02 AR ARP980104944A patent/AR015176A1/es unknown
- 1998-10-05 AU AU87912/98A patent/AU749595B2/en not_active Ceased
- 1998-10-05 HU HU9802224A patent/HUP9802224A1/hu unknown
- 1998-10-05 US US09/166,283 patent/US6162819A/en not_active Expired - Lifetime
- 1998-10-05 CZ CZ983205A patent/CZ320598A3/cs unknown
- 1998-10-05 CA CA2249542A patent/CA2249542C/en not_active Expired - Fee Related
- 1998-10-05 JP JP28234598A patent/JP4426660B2/ja not_active Expired - Fee Related
- 1998-10-05 TR TR1998/01996A patent/TR199801996A2/xx unknown
- 1998-10-06 CN CN98120881A patent/CN1214339A/zh active Pending
- 1998-10-06 PL PL98329042A patent/PL329042A1/xx unknown
- 1998-10-06 BR BR9803880-0A patent/BR9803880A/pt not_active IP Right Cessation
-
2002
- 2002-09-24 US US10/252,825 patent/US6897232B2/en not_active Expired - Lifetime
-
2005
- 2005-04-13 US US11/104,556 patent/US7300950B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR015176A1 (es) | Derivados pirazol y derivados de pirazol condensados que incluyen indazoles, su procedimiento de preparacion, preparado farmaceutico y su utilizacionpara la preparacion de medicamentos. | |
AR004516A1 (es) | Derivados de pirimidina, su uso, procedimientos para prepararlos y medicamentos que los contienen | |
AR037647A1 (es) | Derivados de diarilurea utiles para el tratamiento de enfermedades dependientes de la cinasa de proteina | |
AR050084A1 (es) | Derivados de bencimidazolona como inhibidores de hsp90 | |
AR032361A1 (es) | Derivados de androstano y sales y solvatos de los mismos, su uso para la fabricacion de medicamentos, composiciones farmaceuticas que comprenden tales compuestos, proceso para la preparacion de dichos compuestos, e intermediarios utiles en la preparacion de tales compuestos | |
AR033290A1 (es) | Derivados antiinflamatorios de androstano | |
AR010065A1 (es) | COMPUESTOS HETEROCíCLICOS Y EL USO DE LOS MISMOS PARA LA PREPARACION DE FARMACOS UTILES COMO INHIBIDORES DE LA ADHESION DE LEUCOCITOS Y ANTAGONISTAS DE LA VLA-4 | |
ES2040276T3 (es) | Derivados de la indolizina, procedimiento para su preparacion y composiciones que los contienen. | |
ES2062009T4 (es) | Agentes antifungicos derivados de triazol | |
AR047496A1 (es) | Derivados de diaril-urea en el tratamiento de enfermedades dependientes de la quinasa de proteina | |
AR014313A1 (es) | Derivados de benzosulfona, medicamento que los contiene, procedimiento para su preparacion y su empleo para la manufactura de dicho medicamento | |
GT199900119A (es) | Jarabe antihistaminico estabilizado. | |
AR017852A1 (es) | COMPUESTOS DE PIRAZOLO (3,4-b)PIRIDINA Y SUS SALES, UTILES COMO INHIBIDORES DE LAS PROTEINA-QUINASAS DEPENDIENTES DE CICLINA, Y LAS COMPOSICIONESFARMACEUTICAS QUE LOS CONTIENEN, EVENTUALMENTE ASOCIADOS CON UN AGENTE ANTICANCER. | |
PE20040411A1 (es) | Compuestos de aril cetona pirrolo triazina | |
AR035153A1 (es) | Derivados de carboxamidas y cetonas de dihidrobenzodioxina | |
AR065795A1 (es) | Derivados de aza-piridopirimidinona,metodo de preparacion,medicamentos que los contienen y usos como agentes antitromboticos, antihiperlipidemicos y antidiabeticos,entre otros. | |
AR037907A1 (es) | Derivados de azaindolilalquilamina como ligandos de 5-hidroxitriptamina-6 | |
CR11220A (es) | Derivados de pirimidina 934 | |
ES2158861T3 (es) | 4-imidometil-1-(2'-fenil-2'-oxoetil)-piperidinas como inhibidores de los receptores 5ht2 de la serotonina, su preparacion y sus aplicaciones terapeuticas. | |
ES2044981T3 (es) | Un proceso para la preparacion de nuevos derivados de 4(3h)-quinazolinona. | |
ATE61347T1 (de) | Zytoprotektive derivate zur anwendung bei ischaemischen erkrankungen, ihre herstellung und sie enthaltende zusammensetzungen. | |
ES2073258T3 (es) | Nuevos derivados de la urea, su preparacion y su aplicacion en terapeutica. | |
AR043487A1 (es) | Heterociclos fusionados de pirimidina y usos de los mismos | |
UY27998A1 (es) | Piperazinas sustituidas sustituidas heterocíclicas para el tratamiento de la esquizofrenia | |
AR031486A1 (es) | Derivados de pirimidina |